Green Hills Biotechnology

Biopharmaceutical company developing and commercialising therapeutics for many diseases, including viral infectious diseases and cancer

Green Hills Biotechnology is based in Vienna, Austria and closely cooperates with national and international institutions and hospitals.

Thomas Muster, Ph.D., CEO, CSO
Michael Tscheppe, CFO
Reinhard Zickler, COO
Andrej Egorov, VP Research
Rosemarie Dick-Gudenus, VP Development

Herbert Hild, Ph.D., Chairman
Nikolaus Zacherl, Ph.D.
Christian Mitteregger
Gregor Medinger, Ph.D.

Gersthoferstr. 29-31
1180 Vienna
Austria
Phone: +43-1-3199-670
Fax: +43-1-3196-099

The antiviral products of the company are based on the detailed knowledge of virus-cell interactions. Currently, ELIVIR (against viral respiratory infections)and ONCOFLU (cancer treatment) are in late stage preclinical development; VIRPLUS (screening method) and OPTIVIR are early stage products of the company’s product pipeline which Green Hills Biotechnology hopes to expand over the next years.